Litcius/Paper detail

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

Ziad Bakouny, C. Labaki, Sheena Bhalla, Andrew Schmidt, John A. Steinharter, Jennifer Cocco, Douglas Tremblay, Mark M. Awad, Alaina J. Kessler, Robert I. Haddad, Michelle Evans, Fiona Busser, Michael Wotman, Catherine Curran, Brittney S. Zimmerman, Gabrielle Bouchard, Tomi Jun, Pier Vitale Nuzzo, Qian Qin, Laure Hirsch, Jonathan Feld, Kaitlin M. Kelleher, Danielle Seidman, Hsin-Hui Huang, Heather Anderson-Keightly, Talal El Zarif, Sarah Abou Alaiwi, Catherine M. Champagne, Talia D. Rosenbloom, Penina S. Stewart, Bruce E. Johnson, Quoc‐Dien Trinh, Sara M. Tolaney, Matthew D. Galsky, Toni K. Choueiri, Deborah B. Doroshow

2022Annals of Oncology33 citationsDOIOpen Access PDF

Topics & Concepts

MedicineClinical trialCohortPandemicAccrualCancerOdds ratioCohort studyInternal medicineIntensive care medicineCoronavirus disease 2019 (COVID-19)DiseaseAccountingInfectious disease (medical specialty)BusinessEarningsCOVID-19 and healthcare impactsCOVID-19 Clinical Research StudiesEconomic and Financial Impacts of Cancer
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study | Litcius